Advancing differentiated next-generation MC4R agonists toward first-in-human clinical studies in 2027
- Lead lipidated, long-acting MC4R-selective peptide advancing through IND-enabling and manufacturing activities, with Phase 1 initiation targeted for the first half of calendar 2027
- Preclinical findings demonstrate selective and potent MC4R agonism with minimal to no MC1R activity in tested peptide compounds, supporting the potential to substantially reduce or eliminate MC1R-mediated hyperpigmentation
- Expanding oral MC4R opportunities through next-generation small-molecule development and an oral peptide agonist approach
- Oral small-molecule MC4R-selective agonist Phase 1 study targeted for the second half of calendar 2027
- First-quarter R&D investment in MC4R obesity programs more than doubled year over year, reflecting advancement of key preclinical development activities
- Conference call and webcast scheduled for
November 17, 2026 at11:00 a.m. ET
"MC4R agonism is now a clinically and commercially validated therapeutic approach for rare neuroendocrine obesity disorders, and we believe the next generation of therapies will be defined not only by efficacy, but by meaningful improvements in tolerability, convenience and long-term usability," said
"Our lead lipidated peptide program represents a particularly compelling opportunity," continued
"During the quarter, we continued to advance IND-enabling activities with our long-acting peptide while progressing our next-generation oral small-molecule candidates and additionally exploring oral peptide opportunities. We are targeting the initiation of our first Phase 1 study in the first half of 2027, followed by our oral small-molecule program in the second half of 2027. We believe these programs have the potential to establish a new standard for MC4R-targeted treatment of rare obesity disorders."
MC4R Obesity Program Update
Palatin is advancing a portfolio of MC4R-selective agonists designed to address hypothalamic obesity ("HO"), Prader-Willi syndrome ("PWS"), Bardet-Biedl syndrome ("BBS") and other rare obesity disorders associated with dysfunction of the melanocortin pathway.
The Company's strategy focuses on developing therapies with meaningful efficacy, improved gastrointestinal tolerability, reduced or eliminated MC1R-mediated hyperpigmentation, and dosing characteristics suitable for chronic treatment.
Next-Generation Long-Acting Peptide MC4R Agonists
Palatin is advancing two complementary MC4R-selective peptide series: lipidated PL2000 and non-lipidated PL1000.
- The lead lipidated PL2000 development candidate has demonstrated significant reductions in food intake and body weight following once-weekly subcutaneous administration in a diet-induced obese mouse model.
- Preclinical pharmacokinetic findings support the potential for once-weekly or less frequent dosing in humans.
- Tested compounds from both peptide series have demonstrated potent MC4R agonist activity without acting as agonists at MC1R, supporting the Company's objective of substantially reducing or potentially eliminating hyperpigmentation associated with MC1R activation.
- IND-enabling studies and chemistry, manufacturing and controls ("CMC") activities are ongoing for the lead lipidated peptide candidate.
- Palatin is targeting initiation of a Phase 1 single-ascending-dose/multiple-ascending-dose ("SAD/MAD") clinical study in the first half of calendar 2027, with initial data targeted in the second half of 2027.
- The Company continues to advance its non-lipidated PL1000 peptide series, including controlled-release formulation development, as an additional approach to long-acting MC4R therapy.
Next-Generation Oral MC4R Agonists
Palatin is pursuing oral MC4R-selective therapies through its small-molecule development program and an additional oral peptide agonist approach.
The oral small-molecule program incorporates data and learnings from earlier development candidates, including PL7737, together with advanced medicinal chemistry, computational drug design, artificial intelligence and machine learning capabilities.
- Preclinical studies have identified next-generation oral small-molecule candidates with improved potency and MC4R selectivity relative to earlier compounds, together with favorable oral bioavailability.
- The program is designed to achieve meaningful efficacy with improved tolerability and minimal or no MC1R-mediated hyperpigmentation.
- Lead candidate selection and optimization activities are ongoing, with IND-enabling development targeted for the first half of calendar 2027.
- A Phase 1 SAD/MAD study is targeted to initiate in the second half of calendar 2027, with initial clinical data targeted in the first half of 2028.
- Palatin is also exploring an oral peptide agonist approach as an additional opportunity to expand its MC4R-selective therapeutic portfolio.
Partnering and Out-Licensing Programs
Retinal Diseases –
Palatin continues to collaborate with
The agreement provides for potential future development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of licensed products, if commercialized.
Palatin recognized approximately
PL9643 – Dry Eye Disease
Palatin's exclusive sublicense agreement with
Palatin continues to evaluate strategic partnering and out-licensing opportunities for its bremelanotide co-administration program in obesity, PL8177 or other novel MC1R agonist in ulcerative colitis and its melanocortin receptor agonist program for diabetic nephropathy.
These programs provide opportunities to advance additional assets through strategic collaborations while maintaining Palatin's primary development focus on next-generation MC4R therapies for rare obesity disorders.
Fiscal 2027 First Quarter Ended
For the fiscal first quarter ended
Revenue for the current quarter was attributable to research and development services performed under the
Research and Development Expenses
Research and development expenses were approximately
R&D spending directly related to the Company's MC4R obesity programs increased to approximately
General and Administrative Expenses
General and administrative expenses were approximately
Net Loss
Palatin reported a net loss of approximately
Cash Flows and Cash Position
Net cash used in operating activities was approximately
As of
The Company intends to pursue additional financing and strategic opportunities to support continued advancement of its development programs. Additional funding will be required to execute its planned development activities and fund operations. Accordingly, substantial doubt exists regarding the Company's ability to continue as a going concern for one year following issuance of its financial statements.
Conference Call and Webcast
Palatin will host a conference call and audio webcast on
To listen to the live conference call, dial 1-888-506-0062 (US) or 1-973-528-0011 (International), Participant Access Code: 336522. The audio webcast and replay can be accessed by logging on to the "Investor-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and audio webcast replay will be available one hour after the completion of the call. To access the telephone replay, dial 1-877-481-4010 (US) or 1-919-882-2331 (International), Replay Passcode 54837. The webcast and telephone replay will be available through
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.
Forward-Looking Statements
Statements in this press release that are not historical facts, including statements regarding Palatin's product candidates, potential clinical benefits, efficacy, tolerability, receptor selectivity, dosing frequency, development programs, regulatory submissions, clinical trial initiation and results, collaborations, financing plans and future operations, are forward-looking statements within the meaning of applicable federal securities laws. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the results of preclinical and clinical studies, regulatory decisions, manufacturing and development timelines, Palatin's ability to obtain sufficient financing, the performance of collaborators and licensees, competing therapies, market conditions and other risks described in Palatin's filings with the Securities and Exchange Commission. Palatin undertakes no obligation to update forward-looking statements except as required by law.
| | | ||||
| | and Subsidiary | ||||
| | Consolidated Statements of Operations | ||||
| | (unaudited) | ||||
| | | | | | |
| | | Three Months Ended | | ||
| | | 2026 | | 2025 | |
| | | | | | |
| | REVENUES | | | | |
| | Collaboration and license | $ 361,802 | | $ 8,847,550 | |
| | | | | | |
| | OPERATING EXPENSES | | | | |
| | Research and development | 3,383,743 | | 2,525,766 | |
| | General and administrative | 2,080,414 | | 1,660,731 | |
| | Total operating expenses | 5,464,157 | | 4,186,497 | |
| | | | | | |
| | (Loss) Income from operations | (5,102,355) | | 4,661,053 | |
| | | | | | |
| | OTHER INCOME (EXPENSE) | | | | |
| | Investment income | 46,534 | | 18,483 | |
| | Interest expense | (1,690) | | (2,002) | |
| | Total other (expense) income, net | 44,844 | | 16,481 | |
| | | | | | |
| | NET (LOSS) INCOME | $ (5,057,511) | | $ 4,677,534 | |
| | | | | | |
| | Basic net (loss) income per common share | $ (1.29) | | $ 4.81 | |
| | | | | | |
| | Diluted net (loss) income per common share | $ (1.29) | | $ 4.26 | |
| | | | | | |
| | Weighted average number of common shares | 3,922,464 | | 971,650 | |
| | | | | | |
| | Weighted average number of common shares | 3,922,464 | | 1,098,490 | |
| | | |||
| | and Subsidiary | |||
| | Consolidated Balance Sheets | |||
| | (unaudited) | |||
| | | | | |
| | | | | |
| | ASSETS | | | |
| | Current assets: | | | |
| | Cash and cash equivalents | $ 3,740,424 | | $ 7,492,014 |
| | Accounts receivable | 361,802 | | 300,770 |
| | Prepaid expenses and other current assets | 337,765 | | 371,703 |
| | Total current assets | 4,439,991 | | 8,164,487 |
| | | | | |
| | Property and equipment, net | 101,112 | | 118,064 |
| | Right-of-use assets - operating leases | 155,448 | | 219,677 |
| | Other assets | 21,626 | | 21,626 |
| | Total assets | $ 4,718,177 | | $ 8,523,854 |
| | | | | |
| | LIABILITIES AND STOCKHOLDERS' EQUITY | | | |
| | Current liabilities: | | | |
| | Accounts payable | $ 1,360,530 | | $ 1,109,552 |
| | Accrued expenses | 1,171,975 | | 504,158 |
| | Short-term operating lease liabilities | 126,661 | | 158,263 |
| | Total current liabilities | 2,659,166 | | 1,771,973 |
| | | | | |
| | Long-term operating lease liabilities | 32,932 | | 65,416 |
| | Total liabilities | 2,692,098 | | 1,837,389 |
| | | | | |
| | Stockholders' equity: | | | |
| | Preferred stock of | | | |
| | issued and outstanding designated as follows: | | | |
| | Series A Convertible: authorized 4,030 shares as of | | | |
| | and outstanding 4,030 shares as of | 40 | | 40 |
| | Series D Convertible: authorized 3,400 shares as of | | | |
| | and outstanding 3,400 shares as of | 34 | | 34 |
| | Common stock of | | | |
| | issued and outstanding 1,780,939 shares as of | 17,809 | | 17,793 |
| | Additional paid-in capital | 474,517,501 | | 474,120,392 |
| | Accumulated deficit | (472,509,305) | | (467,451,794) |
| | Total stockholders' equity | 2,026,079 | | 6,686,465 |
| | Total liabilities and stockholders' equity | $ 4,718,177 | | $ 8,523,854 |
| | | | | |
| | | | | |
| | | | | |
| | BS Check | $ - | | $ - |
| | Working Capital | 1,780,825 | | 6,392,514 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-reports-fiscal-first-quarter-2027-financial-results-and-provides-business-update-302941645.html
SOURCE